Grifols, SA (ES:GRF)
BME:GRF
Want to see ES:GRF full AI Analyst Report?
GRF Stock Chart & Stats
€9.05
-€0.12(-1.30%)
At close: 4:00 PM EST
€9.05
-€0.12(-1.30%)
Day’s Range― - ―
52-Week Range€8.01 - €13.70
Previous CloseN/A
Volume312.38K
Average Volume (3M)1.09M
Market Cap
€5.56B
Enterprise Value€14.91B
Total Cash (Recent Filing)€825.49M
Total Debt (Recent Filing)€9.64B
Price to Earnings (P/E)18.7
Beta0.89
Next Earnings
Apr 30, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield1.37%
Share Statistics
EPS (TTM)0.14
Shares Outstanding426,129,800
10 Day Avg. Volume1,216,950
30 Day Avg. Volume1,090,725
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.40
Price to Sales (P/S)0.98
P/FCF Ratio9.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.75Price Target Upside29.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.87
Revenue Forecast (FY)€7.75B
Bulls Say, Bears Say
Bulls Say
Revenue And Profit RecoveryGrifols has moved past the 2022–2023 trough with steady mid-to-high single-digit revenue growth and improved margins. This recovery signals resilient end-market demand for plasma therapies and supports more predictable top-line and operating performance over the next 2–6 months.
Solid Cash Generation And Positive Free Cash FlowMaterial operating cash flow and positive free cash flow provide internal funding for working capital and reinvestment, reducing near-term external financing needs. Sustained FCF supports gradual deleveraging, capex funding for capacity or diagnostics, and operational stability over coming months.
Vertically Integrated Plasma-to-product Model And Recurring Diagnostics RevenueOwning plasma collection, fractionation and commercialization plus a diagnostics franchise with recurring reagent sales creates durable revenue streams and margin capture across the value chain. Vertical integration reduces supply dependency and supports long-term competitive positioning.
Bears Say
High Leverage And Elevated Debt LoadA €9.6B debt stock and ~1.83x leverage materially constrain strategic optionality, increase refinancing and interest-rate vulnerability, and limit the company's ability to make large investments or acquisitions. Elevated leverage raises long-term financial risk over the next several quarters.
Low Cash Coverage Of Total DebtAlthough cash generation improved, operating cash covers only ~0.52x of total debt and FCF growth turned negative, implying deleveraging will be gradual. Limited cash-to-debt coverage increases refinancing pressure and reduces resilience to shocks over a 2–6 month horizon.
Margins Below Historical Peak And Earnings VolatilityImproved margins are encouraging, but net margin is still materially below pre-2020 levels and earnings have been volatile. This reduces confidence in margin sustainability and forecastability, complicating planning for investment, dividend policy, and debt reduction over the medium term.
Grifols News
GRF FAQ
What was Grifols, SA’s price range in the past 12 months?
Grifols, SA lowest stock price was €8.01 and its highest was €13.70 in the past 12 months.
What is Grifols, SA’s market cap?
Grifols, SA’s market cap is €5.56B.
When is Grifols, SA’s upcoming earnings report date?
Grifols, SA’s upcoming earnings report date is Apr 30, 2026 which is in 2 days.
How were Grifols, SA’s earnings last quarter?
Grifols, SA released its earnings results on Feb 26, 2026. The company reported €0.144 earnings per share for the quarter, missing the consensus estimate of €0.255 by -€0.111.
Is Grifols, SA overvalued?
According to Wall Street analysts Grifols, SA’s price is currently Undervalued.
Does Grifols, SA pay dividends?
Grifols, SA pays a Annually dividend of €0.15 which represents an annual dividend yield of 1.37%. See more information on Grifols, SA dividends here
What is Grifols, SA’s EPS estimate?
Grifols, SA’s EPS estimate is 0.14.
How many shares outstanding does Grifols, SA have?
Grifols, SA has 426,129,800 shares outstanding.
What happened to Grifols, SA’s price movement after its last earnings report?
Grifols, SA reported an EPS of €0.144 in its last earnings report, missing expectations of €0.255. Following the earnings report the stock price went up 1.004%.
Which hedge fund is a major shareholder of Grifols, SA?
Currently, no hedge funds are holding shares in ES:GRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.39%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-7.75%
Trailing 12-Months
Company Description
Grifols, SA
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
GRF Stock 12 Month Forecast
Average Price Target
€11.75
▲(29.83% Upside)
Technical Analysis
Almirall
―
Faes Farma
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---